A study conducted by researchers at the Center for Cell-Based Therapy (CTC) highlights key proteins and signaling pathways ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

Machine learning models have seeped into the fabric of our lives, from curating playlists to explaining hard concepts in a ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Tolerance Bio is targeting an often-overlooked organ — the thymus — with cell therapy to help kids with DiGeorge syndrome, and potentially extend lifespan in adults.

Stem cell therapy is an emerging treatment for type 2 diabetes. Although it’s not yet FDA-approved in the United States, it is a rapidly expanding and promising field of research. Stem cells are ...

While CAR T cell therapy—a personalized form of cancer immunotherapy first successfully developed by Carl June, MD, and his team at Penn—has revolutionized treatment for many blood cancers ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...

Despite these advancements, more than 50% of patients with lymphoma do not have long-term remission with anti-CD19 CAR T-cell therapy. These patients have limited treatment options and poor prognoses.

IT’S NOT CURABLE AT THIS POINT. RUNNING OUT OF OPTIONS, HE TRIED A RELATIVELY NEW TREATMENT CALLED CAR-T CELL THERAPY, USING HIS OWN CELLS TO FIGHT THE DISEASE. THE STARTING MATERIALS ...

An international research group led by scientists has now succeeded in a phase 1 clinical trial in testing a novel cell therapy approach that also shows promise for solid tumors. In recent years ...

A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares ...